68Ga-HER2 PET/CT predicts breast cancer treatment response after two chemotherapy cycles

In a prospective study, 68Ga-HER2 PET/CT after two cycles predicted pathologic complete response (pCR): 85% pCR when uptake dropped ≥61% vs 38% if less.

• Baseline 68Ga-HER2 PET/CT could not distinguish patients who would later achieve pCR from those who did not.
• A ≥61% reduction in tracer uptake after the second cycle was associated with an 85% pCR rate, versus 38% when the decline was smaller.
• HER2-targeted molecular imaging may detect treatment response earlier than MRI, which often struggles to separate residual tumor from fibrosis.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.